| 1 |
中国恶性PE诊断与治疗专家共识组．恶性胸腔积液诊断与治疗专家共识[J]. 中华内科杂志，2014, 53(3): 252-256.
|
| 2 |
曾 灏，田攀文. 恶性胸腔积液的诊断研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 247-249.
|
| 3 |
Dorry M, Davidson K, Dash R, et al. Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis[J]. Transl Lung Cancer Res, 2021, 10(6): 2500-2508.
|
| 4 |
刘文媛，刘跃建，高凌云. 良恶性胸腔积液的病因及不同诊断方法的研究进展[J]. 实用医院临床杂志，2019, 1: 216-218.
|
| 5 |
Lucía Ferreiro, Juan SuárezAntelo, Manuel ÁlvarezDobaño José, et al. Malignant pleural effusion: Diagnosis and management[J]. Canad Respir J, 2020, PMID: 33273991.
|
| 6 |
刘 颖，吴金如，夏熙郑，等. 老年胸腔积液患者54例内科胸腔镜检查和胸膜活检分析[J]. 郑州大学学报(医学版), 2010, 45(6): 1036-1038.
|
| 7 |
Wei Liu JL, Ping Zhang QH, Shi Feng LL, et al. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic[J]. Cancer Science, 2019, 110(9): 2941-2959.
|
| 8 |
杨建伯. 中国人口平均寿命及流行病学意义[J]. 中国地方病学杂志，2003, 22(2): 43-46.
|
| 9 |
陈 永，程 莉. 老年胸腔积液病因分析[J]. 现代医药卫生，2006, 22(15): 2329-2330.
|
| 10 |
Chantharakhit C, Sujaritvanichpong N. Developing a prediction score for the diagnosis of malignant pleural effusion: MPE score[J]. Asian Pac J Cancer Prev, 2022, 23(1): 25-31.
|
| 11 |
Shameek Gayen. Malignant pleural effusion: Presentation, diagnosis，and management[J]. Am J Med, 2022, 135(10): 1188-1192.
|
| 12 |
Feng M, Zhu J, Liang L, et al. Diagnostic value of tumor markers for lung adenocarcinoma associated malignant pleural effusion: a validation study and meta-analysis[J]. Int J Clin Oncol, 2017, 22(2): 1-8.
|
| 13 |
Costa Temm, Raghavendra NM, Penido C. Natural heat shock protein 90 inhibitors in cancer and inflammation[J]. Eur J Med Chem, 2020, 189: 112063.
|
| 14 |
Jafari A, Rezaei-tavirani M, Farhadihosseinabadi B, et al. HSP90 and Cochape rones: impact on tumor progression and prospects for molecular-target-ed cancer therapy[J]. Cancer Investigation, 2020, 38(5): 310-328.
|
| 15 |
Yang Q, Zhang P, Wu R, et al. Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible？[J]. Dismarkers, 2018, 2018: 2082840.
|
| 16 |
Guo J, Yu J, Song X, et al. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A Meta-analysis[J]. Open Med, 2017, 12(1): 131-137.
|
| 17 |
陈阳育，徐莉莉，伍燕兵，等. 血清及胸腔积液中四种肿瘤标志物联合应用对良恶性肿瘤诊断价值的评估[J]. 中华肿瘤防治杂志，2021, 28(3): 212-222.
|
| 18 |
吴学虹，王丽燕，杨丽英. 联合检测血清和胸腔积液中肿瘤标志物对良恶性胸腔积液的鉴别诊断价值分析[J]. 中华肿瘤防治杂志，2018, 25(S1): 80-81.
|
| 19 |
Faria DK, Faria CS, Doi D, et al. Hybrid panel of biomarkers can be useful in the diagnosis of pleural and peritoneal effusions[J]. Clin Chim Acta, 2019, 497(10): 48-53.
|
| 20 |
Chen X, Zhang N, Dong J, et al. Reactive oxygen species modulator 1, a novel protein, combined with carcinoembryonic antigen in differentiating malignant from benign pleural effusion[J]. Tumour Biol, 2017, 39(5): 1-8.
|
| 21 |
Braunschweig T, Chung JY, Choi CH, et al. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array[J]. Diagn Pathol, 2015, 10: 53.
|
| 22 |
Ding Q, Sun YB, Zhang JG, et al. Utility and specificity of plasma heat shock protein 90 alpha, CEA, and CA199 as the diagnostic test in colorectal cancer liver metastasis[J]. J Gastr Oncol, 2022, 13(5): 2497-2504.
|
| 23 |
Yuan ZM, Wang LH, Chen C. Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors[J]. Front Oncol, 2022, 12: 963719.
|
| 24 |
Hou Q, Chen S, An Q, et al. Extracellular Hsp90α Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer[J]. Int J Mol Sci, 2021, 22(14): 7747.
|
| 25 |
Zhou W, Yang Y, Wang Z, et al. Impact of HSP90α，CEA, NSE, SCC, and CYFRA21-1 on lung cancer patients[J]. J Healthc Eng, 2021, 2021: 6929971.
|
| 26 |
苏世红，尹永杰，张 玉，等. TAP和HSP90α检测在肺癌恶性胸腔积液诊断及预后评估的价值[J]. 临床肺科杂志，2022, 27(7): 1086-1091.
|
| 27 |
Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds[J]. Expert Opin Biol Ther, 2002, 2(1): 3-24.
|
| 28 |
Roe SM, Prodromou C, O′Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin[J]. J Med Chem, 1999, 42(2): 260-266.
|
| 29 |
Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation[J]. Proc Natl Acad Sci U S A, 1994, 91(18): 8324-8328.
|
| 30 |
Marcu MG, Chadli A, Bouhouche I, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone[J]. J Biol Chem, 2000, 275(47): 37181-37186.
|
| 31 |
Zhang T, Li Y, Yu Y, et al. Characterization of celastrol to inhibit hsp90 and cdc37 interaction[J]. J Biol Chem, 2009, 284(51): 35381- 35389.
|